Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenova Group PLC

www.xenova.co.uk

Latest From Xenova Group PLC

Busy Times and Divergent Strategies for Celtic Pharma's Follow-On Funds

The various Celtic funds (there are three, with two sprouting from the original Celtic Pharma I Holdings established in 2004) posted a very busy January, closing deals involving Kolltan Pharmaceuticals Inc., Cantab Pharmaceuticals PLC, Inspiration Biopharmaceuticals Inc. and PolyTherics Ltd. But the details of these transactions help illustrate how the two actively investing successor funds have established fundamentally different investment strategies, even if those strategies can overlap at times.
BioPharmaceutical Business Strategies

Celtic Pharma Sees a Role for Private Equity in Biotech

The recently launched private equity firm Celtic Pharma aims to bridge the gap between biotech companies that have trouble financing R&D for mid- to late-stage projects and the Big Pharma firms desperate to rebuild their pipelines. The group's first fund, at around $1 billion, aims to bring together approximately 20 late-stage projects, take each through to regulatory approval, and license them out to the highest bidder.
BioPharmaceutical Clinical Trials

Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
BioPharmaceutical Business Strategies

Code Securities: Banking on a Biotech Revival

When Chris Collins, former head of life sciences at WestLB Panmure, launched Code Securities in November 2003, he was taking a big gamble: biotech deals and IPOs are still at a low ebb, so is investor confidence. Collins is betting on a pick up, hoping that some of Europe's biotechs will see his experienced, dedicated team as a credible, more stable alternative to the bulge bracket banks, many of which were forced to abandon their smaller clients during the downturn.
Europe Business Strategies
See All

Company Information

UsernamePublicRestriction

Register